Pathway candidateNCBI-verifiedprotein-coding

CHD1

chromodomain helicase DNA binding protein 1

NCBI Gene: 1105 Ensembl GeneCards UniProt: O14646

Pathway candidate — not linked to PFS or PSSD by any record here

CHD1 is in the library because it belongs to the epigenetic regulation family. No study, report or commentary in the corpus names it, so a variant in CHD1 is not, by itself, evidence of anything related to post-drug syndromes.

Gene summary

A protein-coding gene on chromosome 5 (epigenetic regulation). The CHD family of proteins is characterized by the presence of chromo (chromatin organization modifier) domains and SNF2-related helicase/ATPase domains. CHD genes alter gene expression possibly by modification of chromatin structure thus altering access of the transcriptional apparatus to its chromosomal DNA template.

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: ATP-dependent chromatin remodeler CHD1
Function: ATP-dependent chromatin-remodeling factor which functions as substrate recognition component of the transcription regulatory histone acetylation (HAT) complex SAGA. Regulates polymerase II transcription. Also required for efficient transcription by RNA polymerase I, and more specifically the polymerase I transcription termination step. Regulates negatively DNA replication. Not only involved in transcription-related chromatin-remodeling, but also required to maintain a specific chromatin configuration across the genome. Is also associated with histone deacetylase (HDAC) activity (By similarity). Required for the bridging of SNF2, the FACT complex, the PAF complex as well as the U2 snRNP complex to H3K4me3. Functions to modulate the efficiency of pre-mRNA splicing in part through physical bridging of spliceosomal components to H3K4me3. Required for maintaining open chromatin and pluripotency in embryonic stem cells (By similarity).
Subcellular location: Nucleus; Cytoplasm.
Tissue specificity: Expressed in many tissues including in the brain, where the highest level of expression is found in the cerebellum and basal ganglia.
Associated conditions: Pilarowski-Bjornsson syndrome (PILBOS).

Source: UniProtKB/Swiss-Prot O14646, release 2026_03, licensed CC BY 4.0. This is the protein’s normal biology, not evidence about post-drug syndromes; associated conditions are inherited disorders of the gene, not PFS, PSSD or PRSD.

Why its pathway is in the library

Epigenetic persistence is the leading hypothesis for why post-drug syndromes endure after the drug is gone; chromatin regulators are therefore priority candidates in any persistence mechanism.

Written for the whole epigenetic regulation family, not for CHD1 specifically.

Mentioned in 0 corpus records

No corpus record names CHD1 directly yet. It is in the library because it sits in a pathway the corpus tracks (Epigenetic regulation).

Also in epigenetic regulation

All 130 genes

Browse by family on the gene families page.

Gene summary

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: ATP-dependent chromatin remodeler CHD1
Function: ATP-dependent chromatin-remodeling factor which functions as substrate recognition component of the transcription regulatory histone acetylation (HAT) complex SAGA. Regulates polymerase II transcription. Also required for efficient transcription by RNA polymerase I, and more specifically the polymerase I transcription termination step. Regulates negatively DNA replication. Not only involved in transcription-related chromatin-remodeling, but also required to maintain a specific chromatin configuration across the genome. Is also associated with histone deacetylase (HDAC) activity (By similarity). Required for the bridging of SNF2, the FACT complex, the PAF complex as well as the U2 snRNP complex to H3K4me3. Functions to modulate the efficiency of pre-mRNA splicing in part through physical bridging of spliceosomal components to H3K4me3. Required for maintaining open chromatin and pluripotency in embryonic stem cells (By similarity).
Subcellular location: Nucleus; Cytoplasm.
Tissue specificity: Expressed in many tissues including in the brain, where the highest level of expression is found in the cerebellum and basal ganglia.
Associated conditions: Pilarowski-Bjornsson syndrome (PILBOS).